Research Use Only. KIRhub outputs are computational research artifacts. They are not validated for clinical decision-making, diagnosis, or treatment.

← Cohorts · breast-umap@18

TCGA-AC-A6IX-01A-12R-A32P-07

— · A

477c0ba2-f7f4-524d-87ee-da75364a2c52

Score in workbench →

Clinical attributes

From the source cohort, normalized into canonical keys plus the project's native columns.

cancer_type
—
cancer_type_detailed
—
subtype
A
subtype
A
overall_survival_months
12

GSVA pathway preview (50 Hallmark scores)

MeasuredDerivedReference

Top 10 most elevated and top 10 most suppressed Hallmark pathways for this sample.

Top 10 elevated

  • MYOGENESIS+0.330
  • INTERFERON_ALPHA_RESPONSE+0.320
  • KRAS_SIGNALING_UP+0.280
  • ANGIOGENESIS+0.250
  • EPITHELIAL_MESENCHYMAL_TRANSITION+0.250
  • FATTY_ACID_METABOLISM+0.230
  • PANCREAS_BETA_CELLS+0.230
  • IL6_JAK_STAT3_SIGNALING+0.220
  • P53_PATHWAY+0.220
  • INTERFERON_GAMMA_RESPONSE+0.210

Top 10 suppressed

  • E2F_TARGETS-0.570
  • G2M_CHECKPOINT-0.550
  • MYC_TARGETS_V2-0.520
  • MYC_TARGETS_V1-0.500
  • MTORC1_SIGNALING-0.420
  • MITOTIC_SPINDLE-0.300
  • SPERMATOGENESIS-0.290
  • UNFOLDED_PROTEIN_RESPONSE-0.290
  • GLYCOLYSIS-0.270
  • ANDROGEN_RESPONSE-0.180

Patient twins — nearest pathway neighbors

MeasuredDerived

10 samples closest to this one in 50-dim pathway space, drawn from the Pathway Atlas. Cosine similarity = 1 means identical pathway state.

10 twins match this tumor's tissue · 0 come from a different tissue of origin

#SampleCancer typeSubtypecos similarity
1TCGA-GM-A4E0-01A-12R-A266-07
breast-umap@18
—A0.868
220040019.LumA
breast-umap@18
—A0.852
3SRR8518288
breast-umap@18
—A0.847
4TCGA-64-1681-01A-11R-2066-07
lung-landscapes@6
—cohortA10.844
5TCGA-D8-A1JU-01A-11R-A13Q-07
breast-umap@18
—A0.843
6TCGA-AC-A3HN-01A-11R-A213-07
breast-umap@18
—A0.842
7SRR1313130
breast-umap@18
—A0.834
8BSR_14_0175_A4_S56
breast-umap@18
—A0.834
9SRR12475153
colon-landscapes@1
——0.831
10SRR26320092
bladder-landscape@3
——0.830

Per-pathway drug coverage

ModeledCalibratedDerived

For each elevated pathway in this tumor, the best-reversing drug across the catalog. Uncovered pathways = unmet need at pathway level for this one patient.

0 of 27 elevated pathways have at least one drug that meaningfully reverses them.

Pathway (elevated)tumor scoreBest drugreversal magnitude
MYOGENESIS0.330Inavolisib— uncovered
INTERFERON_ALPHA_RESPONSE0.320Inavolisib— uncovered
KRAS_SIGNALING_UP0.280Inavolisib— uncovered
ANGIOGENESIS0.250Remibrutinib— uncovered
EPITHELIAL_MESENCHYMAL_TRANSITION0.250Inavolisib— uncovered
FATTY_ACID_METABOLISM0.230Inavolisib— uncovered
PANCREAS_BETA_CELLS0.230Cobimetinib— uncovered
IL6_JAK_STAT3_SIGNALING0.220Inavolisib— uncovered
P53_PATHWAY0.220Idelalisib— uncovered
INTERFERON_GAMMA_RESPONSE0.210Idelalisib— uncovered
TGF_BETA_SIGNALING0.210Inavolisib— uncovered
ADIPOGENESIS0.200Inavolisib— uncovered
HEDGEHOG_SIGNALING0.190Inavolisib— uncovered
UV_RESPONSE_DN0.160Inavolisib— uncovered
XENOBIOTIC_METABOLISM0.150Inavolisib— uncovered
TNFA_SIGNALING_VIA_NFKB0.120Inavolisib— uncovered
APICAL_JUNCTION0.110Inavolisib— uncovered
APOPTOSIS0.110Idelalisib— uncovered
WNT_BETA_CATENIN_SIGNALING0.110Inavolisib— uncovered
APICAL_SURFACE0.100Temsirolimus— uncovered